Trial Search Results
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Stanford is currently accepting patients for this trial.
- Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated
with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.
- Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or
- Patients with hepatitis B or hepatitis C viral infections not associated with liver
-Patients will be excluded if, upon looking through their medical records, information
required for data analysis are missing.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study